organization · Reporting owner
GNI Hong Kong Ltd
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GYRE THERAPEUTICS, INC.
Report date October 27, 2023 · Filed October 27, 2023
Section 16 reporting ended · disclosed 2023-10-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-27 transaction · row 1
1 source rowRow 1 · 2023-10-27 · Other · Disposed 5,371,304 · Balance 0 F1: Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376. |
| Series X Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-10-27 · Other · Disposed 10,577 · Balance 0 F2: Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022). F1: Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376.
F2: Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 27, 2023 Filed Oct 27, 2023 23:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherSeries X Convertible Preferred Stock · Derivative | 10,577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-050019 · form4.xml · derivative · entry 2 GNI Hong Kong Ltd · CIK 0001958509 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,770,000 shares Expires not disclosed F2 · derivative.exercise_price: Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022). F1 · kind: Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376. F2 · price: Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022). F2 · derivative.exercise_date: Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022). F2 · derivative.expiration_date: Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022). Read SEC document |
| October 27, 2023 Filed Oct 27, 2023 23:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherCommon Stock | 5,371,304 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-050019 · form4.xml · nonDerivative · entry 1 GNI Hong Kong Ltd · CIK 0001958509 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376. F1 · price: Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 5,371.303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042366 · form4.xml · nonDerivative · entry 2 GNI Group Ltd. · CIK 0001958461 · 10% owner GNI Hong Kong Ltd · CIK 0001958509 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F5 · ownership.direct: These securities are held by GNI HK. F6 · ownership.direct: GNI HK, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI HK and, therefore, a "ten percent holder" hereunder. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 895.217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042366 · form4.xml · nonDerivative · entry 1 GNI Group Ltd. · CIK 0001958461 · 10% owner GNI Hong Kong Ltd · CIK 0001958509 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F3 · ownership.direct: These securities are held by GNI Group Ltd. ("GNI Japan"). F4 · ownership.direct: GNI Hong Kong Ltd. ("GNI HK") disclaims beneficial ownership of the securities held by GNI Japan for purposes of Rule 16a-1(a)(2), except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.